loading
Precedente Chiudi:
$17.45
Aprire:
$17.73
Volume 24 ore:
247.08K
Relative Volume:
7.98
Capitalizzazione di mercato:
$143.75M
Reddito:
$56.54M
Utile/perdita netta:
$-30.70M
Rapporto P/E:
-52.31
EPS:
-0.39
Flusso di cassa netto:
$-31.05M
1 W Prestazione:
+41.96%
1M Prestazione:
+79.26%
6M Prestazione:
+65.32%
1 anno Prestazione:
+42.66%
Intervallo 1D:
Value
$17.52
$21.28
Intervallo di 1 settimana:
Value
$14.33
$21.28
Portata 52W:
Value
$10.00
$24.40

Cidara Therapeutics Inc Stock (CDTX) Company Profile

Name
Nome
Cidara Therapeutics Inc
Name
Telefono
858-752-6170
Name
Indirizzo
6310 NANCY RIDGE DRIVE, SAN DIEGO, CA
Name
Dipendente
73
Name
Cinguettio
@CidaraThera
Name
Prossima data di guadagno
2024-10-31
Name
Ultimi documenti SEC
Name
CDTX's Discussions on Twitter

Confronta CDTX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
CDTX 20.40 143.75M 56.54M -30.70M -31.05M -0.39
VRTX 450.97 116.14B 10.63B -479.80M -1.35B 13.33
REGN 738.00 81.10B 13.85B 4.65B 3.32B 35.06
ARGX 605.92 36.23B 1.86B -40.29M -1.28B -4.16
ALNY 244.89 31.59B 2.09B -332.26M 16.06M -4.14
BNTX 113.13 27.12B 3.30B -501.07M 1.03B 11.54

Cidara Therapeutics Inc Stock (CDTX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2024-08-14 Aggiornamento H.C. Wainwright Neutral → Buy
2021-12-03 Ripresa H.C. Wainwright Buy
2021-09-22 Aggiornamento WBB Securities Buy → Strong Buy
2021-03-04 Iniziato Aegis Capital Buy
2019-09-04 Aggiornamento Wedbush Neutral → Outperform
2018-07-26 Iniziato Citigroup Buy
2017-04-21 Iniziato Raymond James Strong Buy
2017-04-17 Reiterato H.C. Wainwright Buy
2017-04-12 Iniziato Ladenburg Thalmann Buy
2017-04-11 Ripresa Wedbush Outperform
2017-02-22 Reiterato H.C. Wainwright Buy
2017-02-22 Aggiornamento WBB Securities Sell → Hold
2016-12-21 Ripresa Leerink Partners Outperform
2016-12-19 Iniziato H.C. Wainwright Buy
2016-09-23 Downgrade WBB Securities Hold → Sell
2015-10-09 Aggiornamento WBB Securities Sell → Hold
2015-05-11 Iniziato Jefferies Buy
2015-05-11 Iniziato Leerink Partners Outperform
2015-05-11 Iniziato Needham Buy
2015-05-11 Iniziato Wedbush Outperform
2015-04-23 Iniziato WBB Securities Sell
Mostra tutto

Cidara Therapeutics Inc Borsa (CDTX) Ultime notizie

pulisher
Nov 21, 2024

Cidara: Potential To Change Flu Prophylaxis Landscape With CD388 - Seeking Alpha

Nov 21, 2024
pulisher
Nov 21, 2024

Cidara to raise up to $105 million in private placement - The Pharma Letter

Nov 21, 2024
pulisher
Nov 21, 2024

Cidara Therapeutics Shares Surge 26% on $105 Mln Private Placement - MarketWatch

Nov 21, 2024
pulisher
Nov 21, 2024

Cidara Therapeutics announces $105 million private placement - Investing.com

Nov 21, 2024
pulisher
Nov 21, 2024

Cidara Therapeutics Announces $105 Million Private Placement - GlobeNewswire

Nov 21, 2024
pulisher
Nov 21, 2024

Cidara Therapeutics Secures $105M Private Placement Led by Venrock Healthcare | CDTX Stock News - StockTitan

Nov 21, 2024
pulisher
Nov 19, 2024

Cidara Therapeutics to Participate in Evercore 7th Annual HealthCONx Conference - GlobeNewswire

Nov 19, 2024
pulisher
Nov 19, 2024

Cidara Therapeutics CEO to Present at Evercore HealthCONx Conference | CDTX Stock News - StockTitan

Nov 19, 2024
pulisher
Nov 17, 2024

(CDTX) Technical Data - Stock Traders Daily

Nov 17, 2024
pulisher
Nov 14, 2024

HC Wainwright Has Positive Outlook of CDTX FY2024 Earnings - MarketBeat

Nov 14, 2024
pulisher
Nov 11, 2024

Cidara Therapeutics (NASDAQ:CDTX) Given Buy Rating at HC Wainwright - MarketBeat

Nov 11, 2024
pulisher
Nov 08, 2024

Analysts Set Cidara Therapeutics, Inc. (NASDAQ:CDTX) PT at $29.67 - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cidara Therapeutics (NASDAQ:CDTX) Now Covered by Guggenheim - MarketBeat

Nov 08, 2024
pulisher
Nov 08, 2024

Cidara Therapeutics: Q3 Earnings Snapshot - Houston Chronicle

Nov 08, 2024
pulisher
Nov 07, 2024

Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results - GlobeNewswire

Nov 07, 2024
pulisher
Nov 07, 2024

Cidara's Q3 Loss Widens to $16M Despite Strong CD388 Trial Progress and Cash Position | CDTX Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 06, 2024

(CDTX) Pivots Trading Plans and Risk Controls - Stock Traders Daily

Nov 06, 2024
pulisher
Oct 31, 2024

Will Rezafungin Trial Data ReSTORE Investors' Faith In Cidara? - RTTNews

Oct 31, 2024
pulisher
Oct 31, 2024

Cidara Therapeutics to Participate in Two Upcoming November Investor Conferences - GlobeNewswire

Oct 31, 2024
pulisher
Oct 30, 2024

How Cidara Got Its Molecule Back - BioProcess Online

Oct 30, 2024
pulisher
Oct 29, 2024

Cidara Therapeutics, Inc. (NASDAQ:CDTX) Sees Significant Drop in Short Interest - MarketBeat

Oct 29, 2024
pulisher
Oct 23, 2024

Cidara Therapeutics, Inc. (CDTX) Stock Price & Chart | Trade Now - Capital.com

Oct 23, 2024
pulisher
Oct 23, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives “Buy” Rating from HC Wainwright - Defense World

Oct 23, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Receives Buy Rating from HC Wainwright - MarketBeat

Oct 22, 2024
pulisher
Oct 22, 2024

Cidara Therapeutics (NASDAQ:CDTX) Stock Price Passes Below Fifty Day Moving AverageWhat's Next? - MarketBeat

Oct 22, 2024
pulisher
Oct 16, 2024

Cidara Therapeutics Announces Two Presentations on Drug-Fc Conjugate, CD388, at IDWeek 2024 - GlobeNewswire

Oct 16, 2024
pulisher
Oct 16, 2024

(CDTX) Investment Analysis and Advice - Stock Traders Daily

Oct 16, 2024
pulisher
Oct 14, 2024

Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 14, 2024
pulisher
Oct 14, 2024

Invasive Fungal Infection Market 2034 | Key Brands -Cidara Therapeutics, Basilea Pharmaceutica, Pfizer, GlaxoSmithKline, – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 05, 2024

(CDTX) On The My Stocks Page - Stock Traders Daily

Oct 05, 2024
pulisher
Oct 04, 2024

Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Oct 04, 2024
pulisher
Oct 02, 2024

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - Marketscreener.com

Oct 02, 2024
pulisher
Oct 02, 2024

Shattuck Labs stock craters following pipeline and job cuts - Pharmaceutical Technology

Oct 02, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on - GlobeNewswire

Sep 25, 2024
pulisher
Sep 25, 2024

Cidara Therapeutics Announces Two Presentations on Innovative Drug-Fc Conjugate, CD388, at the 2024 OPTIONS XII for the Control of Influenza Conference - StockTitan

Sep 25, 2024
pulisher
Sep 24, 2024

How to Take Advantage of moves in (CDTX) - Stock Traders Daily

Sep 24, 2024
pulisher
Sep 24, 2024

Long-acting Antiviral for Pre-exposure Protection Against Influenza Launches Phase 2b Study - Precision Vaccinations

Sep 24, 2024
pulisher
Sep 24, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 24, 2024

Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World

Sep 24, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 By Investing.com - Investing.com Canada

Sep 23, 2024
pulisher
Sep 23, 2024

Codexis, Inc. (NASDAQ:CDXS) Major Shareholder Opaleye Management Inc. Purchases 45,000 Shares - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cadence Design Systems Inc. stock rises Monday, still underperforms market - MarketWatch

Sep 23, 2024
pulisher
Sep 23, 2024

Xponance Inc. Has $24.15 Million Holdings in Cadence Design Systems, Inc. (NASDAQ:CDNS) - Defense World

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics begins phase 2b trial for flu prophylaxis - Investing.com India

Sep 23, 2024
pulisher
Sep 23, 2024

CTXR’s price-to-book ratio: An indicator of the company’s performance - US Post News

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara starts Phase 2b trial of influenza drug CD388 - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase - GlobeNewswire

Sep 23, 2024
pulisher
Sep 23, 2024

Cidara Therapeutics Announces First Subjects Dosed in Phase 2b NAVIGATE Trial Evaluating CD388 for the Prevention of Seasonal Influenza - StockTitan

Sep 23, 2024
pulisher
Sep 20, 2024

Biotechs investigate ways to adapt to new clinical trial regulation and economic flux - Yahoo Finance

Sep 20, 2024
pulisher
Sep 20, 2024

Cidara Therapeutics expands Scientific Advisory Board By Investing.com - Investing.com Canada

Sep 20, 2024
pulisher
Sep 19, 2024

Cardlytics Inc [NASDAQ: CDLX] Sees Increase in Stock Value - Knox Daily

Sep 19, 2024

Cidara Therapeutics Inc Azioni (CDTX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$71.72
price up icon 1.89%
$19.00
price up icon 3.15%
$41.11
price up icon 7.48%
$372.89
price up icon 1.51%
$190.51
price down icon 2.08%
$113.13
price up icon 4.53%
Capitalizzazione:     |  Volume (24 ore):